[IMGN] ImmunoGen, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.64 Change: 0.08 (5.13%)
Ext. hours: Change: 0 (0%)

chart IMGN

Refresh chart

Strongest Trends Summary For IMGN

IMGN is in the medium-term up 42% in 1 month and down -46% below S&P in 7 months. In the long-term up 73% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the t

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 98.97% Sales Growth - Q/Q-76.34% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.42% ROE-95.13% ROI
Current Ratio5.22 Quick Ratio5.1 Long Term Debt/Equity Debt Ratio0.38
Gross Margin Operating Margin-71.01% Net Profit Margin-72.15% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.43 M Cash From Investing Activities-5.03 M Cash From Operating Activities-26.84 M Gross Profit
Net Profit-30.47 M Operating Profit-25.09 M Total Assets313.82 M Total Current Assets278.11 M
Total Current Liabilities35.81 M Total Debt Total Liabilities278.72 M Total Revenue12.61 M
Technical Data
High 52 week12.95 Low 52 week3.94 Last close5.46 Last change-1.8%
RSI57.53 Average true range0.42 Beta1.44 Volume965.36 K
Simple moving average 20 days11.98% Simple moving average 50 days2.37% Simple moving average 200 days-37.2%
Performance Data
Performance Week14.23% Performance Month2.25% Performance Quart-33.5% Performance Half-50.54%
Performance Year-18.51% Performance Year-to-date13.75% Volatility daily5.09% Volatility weekly11.37%
Volatility monthly23.31% Volatility yearly80.74% Relative Volume259.72% Average Volume2.72 M
New High New Low

News

2019-01-18 15:00:19 | Have Insiders Been Selling ImmunoGen, Inc. NASDAQ:IMGN Shares This Year?

2019-01-09 07:39:50 | The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

2019-01-08 16:01:00 | ImmunoGen Announces Sale of Residual Kadcyla Royalties

2019-01-07 17:20:00 | Why ImmunoGen Jumped Today

2019-01-02 08:30:00 | ImmunoGen Announces Webcast of Presentation and Q&A at the 37th Annual J.P. Morgan Healthcare Conference

2018-12-26 16:18:00 | Why ImmunoGen Shot Up 13% Today

2018-12-17 21:52:44 | Hedge Funds Are Betting On ImmunoGen, Inc. IMGN

2018-12-12 07:55:00 | Market Trends Toward New Normal in Marriott International, Duke Energy, ImmunoGen, Newell Brands, Vail Resorts, and Fiserv — Emerging Consolidated Expectations, Analyst Ratings

2018-12-06 14:49:07 | Roche's Kadcyla Halves Death Risk in Breast Cancer Study

2018-12-02 17:51:20 | The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

2018-12-02 09:30:02 | ImmunoGen IMGN Down 7.2% Since Last Earnings Report: Can It Rebound?

2018-12-01 10:31:00 | ImmunoGen Presents New Data Highlighting Potential of Novel ADCs in Oral Presentations at ASH Annual Meeting

2018-11-27 07:32:26 | The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial

2018-11-26 16:47:15 | Former Aveo exec resigns as ImmunoGen CFO after fraud verdict

2018-11-26 16:01:00 | ImmunoGen Announces Resignation of Chief Financial Officer

2018-11-25 09:41:17 | The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings

2018-11-21 11:23:32 | Former Aveo CFO misled biotech's investors, jury finds

2018-11-20 08:31:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?

2018-11-14 11:35:00 | Healthcare Stocks with Turnaround Potential

2018-11-12 07:32:00 | How Has Cara Therapeutics’ 2018 Performance Shaken Out?

2018-11-09 14:12:00 | ImmunoGen Waits to Leap "Forward"

2018-11-07 20:28:22 | Here's Why ImmunoGen Closed Almost 12% Up on Wednesday

2018-11-07 09:46:29 | Here's Why ImmunoGen Shares Lost 42.7% in October

2018-11-07 08:20:00 | Report: Developing Opportunities within TE Connectivity, EnPro Industries, Innophos, Ameren, ImmunoGen, and ICF International — Future Expectations, Projections Moving into 2018

2018-11-06 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

2018-11-05 11:01:53 | How ImmunoGen Inc NASDAQ:IMGN Can Impact Your Portfolio Volatility

2018-11-05 09:35:02 | ImmunoGen IMGN Beats on Earnings in Q3, Lowers Guidance

2018-11-02 12:25:46 | Edited Transcript of IMGN earnings conference call or presentation 2-Nov-18 12:00pm GMT

2018-11-02 12:12:15 | Immunogen Inc IMGN Q3 2018 Earnings Conference Call Transcript

2018-11-02 10:43:46 | MARKETS: Today's job numbers might have been too good and could spook stocks

2018-11-02 09:40:01 | ImmunoGen IMGN Reports Q3 Loss, Lags Revenue Estimates

2018-11-02 08:36:35 | ImmunoGen: 3Q Earnings Snapshot

2018-11-02 06:30:00 | ImmunoGen Reports Recent Progress and Third Quarter 2018 Operating Results

2018-11-01 14:55:52 | Q3 Earnings Outlook For ImmunoGen

2018-11-01 09:01:00 | ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 60th ASH Annual Meeting

2018-10-26 10:30:02 | ImmunoGen IMGN Q3 Earnings Preview: What to Look Out For

2018-10-22 11:05:00 | Here's Why ImmunoGen Fell Today

2018-10-20 06:30:00 | ImmunoGen Presents Initial Data from FORWARD II Expansion Cohort Assessing Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO 2018 Congress

2018-10-18 16:30:00 | ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2018 Operating Results

2018-10-15 10:30:00 | Cancer Companies to Watch

2018-10-14 13:21:15 | The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results And IPOs

2018-10-10 08:30:00 | Report: Developing Opportunities within Southwest Airlines, Select Income REIT, Oxford Industries, ImmunoGen, Navigant Consulting, and TrueBlue — Future Expectations, Projections Moving into 2018

2018-10-08 18:05:00 | ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA at ESMO

2018-10-08 09:50:01 | Are Options Traders Betting on a Big Move in ImmunoGen IMGN Stock?

2018-10-05 17:00:00 | Why ImmunoGen Inc. Dropped 8% Today

2018-10-04 17:53:17 | Why ImmunoGen, Inc. Fell 10.6% on Thursday

2018-09-24 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

2018-09-19 08:31:37 | Who Owns Most Of ImmunoGen Inc NASDAQ:IMGN?

2018-08-27 16:30:00 | ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

2018-08-06 07:45:00 | Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble — Discovering Underlying Factors of Influence